Total U.S. pharma and biotech product sales 5 years after launch 2007-2017

Total U.S. pharmaceutical and biotech revenues for products 5 years after launch from 2007 to 2017 (in billion U.S. dollars)

by Matej Mikulic, last edited Feb 18, 2019
Total U.S. pharma and biotech product sales 5 years after launch 2007-2017 This statistic depicts the total pharmaceutical and biotech product revenues in the United States of products five years after launch, from 2007 to 2017. In 2010, product revenues in the U.S. totaled 12.5 billion U.S. dollars for products launched 5 years before.
Pharma and biotech products

Newer pharmaceutical and biotechnology products have generated increasingly large amounts of revenues after five years of launch. In 2008, revenues were at 5.6 billion U.S. dollars but had skyrocketed to some 31 billion U.S. dollars in 2017. The average cost of developing a new pharmaceutical or biotech entity has increased from 451 million U.S. dollars in 1991 to some 1.5 billion U.S. dollars in the 2010s. Many companies that had once focused primarily on pharmaceuticals have begun to integrate biotechnology in their research, which has minimized the separation between the two industries.

Pharmaceuticals are most commonly manufactured through chemical synthesis processes while biotechnology pharmaceuticals are products created within living organisms such as bacteria and yeast. Recently, biological drugs have become the most prominent products in the medicinal industry. For example, Humira, otherwise known as adalimumab, was approved in the United States by the Food and Drug Administration (FDA) in 2008. Humira is marketed by AbbVie and is used as an anti-inflammatory drug. It has since become one of the largest grossing medical products in the world, generating about 16 billion U.S. dollars in 2015. In the United States, Humira generated 13.6 billion U.S. dollars in revenue in 2016. Expenditure on biologics is expected to increase to 221 billion U.S. dollars globally by 2017.
Show more

Total U.S. pharmaceutical and biotech revenues for products 5 years after launch from 2007 to 2017 (in billion U.S. dollars)

Loading statistic...
Revenue in billion U.S. dollars
2017**31.6
201611
201523.7
201419.8
201312.3
2012*13.9
201111.9
201012.5
20095.4
20085.6
20074.3
Revenue in billion U.S. dollars
2017**31.6
201611
201523.7
201419.8
201312.3
2012*13.9
201111.9
201012.5
20095.4
20085.6
20074.3
Download Settings Share
Download started
Please be patient - this may take a moment
by Matej Mikulic, last edited Feb 18, 2019
This statistic depicts the total pharmaceutical and biotech product revenues in the United States of products five years after launch, from 2007 to 2017. In 2010, product revenues in the U.S. totaled 12.5 billion U.S. dollars for products launched 5 years before.
Pharma and biotech products

Newer pharmaceutical and biotechnology products have generated increasingly large amounts of revenues after five years of launch. In 2008, revenues were at 5.6 billion U.S. dollars but had skyrocketed to some 31 billion U.S. dollars in 2017. The average cost of developing a new pharmaceutical or biotech entity has increased from 451 million U.S. dollars in 1991 to some 1.5 billion U.S. dollars in the 2010s. Many companies that had once focused primarily on pharmaceuticals have begun to integrate biotechnology in their research, which has minimized the separation between the two industries.

Pharmaceuticals are most commonly manufactured through chemical synthesis processes while biotechnology pharmaceuticals are products created within living organisms such as bacteria and yeast. Recently, biological drugs have become the most prominent products in the medicinal industry. For example, Humira, otherwise known as adalimumab, was approved in the United States by the Food and Drug Administration (FDA) in 2008. Humira is marketed by AbbVie and is used as an anti-inflammatory drug. It has since become one of the largest grossing medical products in the world, generating about 16 billion U.S. dollars in 2015. In the United States, Humira generated 13.6 billion U.S. dollars in revenue in 2016. Expenditure on biologics is expected to increase to 221 billion U.S. dollars globally by 2017.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Biotech industry
Biotech industry

All Information
in one Presentation

Biotech industry

Everything On "Biotech industry" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Biotech industry"
  • Global overview
  • U.S. companies
  • Research & development
  • Products
  • Funding/investment
  • Biotech in agriculture
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.